Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 191 entries
Sorted by: Best Match Show Resources per page
Temporal Associations and Outcomes of Breast Cancer and Heart Failure in Postmenopausal Women.

JACC. CardioOncology

Lam PH, Barac A, Nohria A, Reding KW, Najjar SS, Fonarow GC, Pan K, Sheriff H, Morgan CJ, Chlebowski RT, Klein L, Eaton CB, Howard BV, Ahmed A, Mohammed SF.
PMID: 34396268
JACC CardioOncol. 2020 Nov 17;2(4):567-577. doi: 10.1016/j.jaccao.2020.09.005. eCollection 2020 Nov.

BACKGROUND: Heart failure (HF) and breast cancer are 2 of the leading causes of death in postmenopausal women. The temporal association between HF and breast cancer in postmenopausal women has not been described.OBJECTIVES: This study sought to examine the...

Cite
Lam PH, Barac A, Nohria A, et al. Temporal Associations and Outcomes of Breast Cancer and Heart Failure in Postmenopausal Women. JACC CardioOncol. 2020;2(4):567-577doi: 10.1016/j.jaccao.2020.09.005.
Lam, P. H., Barac, A., Nohria, A., Reding, K. W., Najjar, S. S., Fonarow, G. C., Pan, K., Sheriff, H., Morgan, C. J., Chlebowski, R. T., Klein, L., Eaton, C. B., Howard, B. V., Ahmed, A., & Mohammed, S. F. (2020). Temporal Associations and Outcomes of Breast Cancer and Heart Failure in Postmenopausal Women. JACC. CardioOncology, 2(4), 567-577. https://doi.org/10.1016/j.jaccao.2020.09.005
Lam, Phillip H, et al. "Temporal Associations and Outcomes of Breast Cancer and Heart Failure in Postmenopausal Women." JACC. CardioOncology vol. 2,4 (2020): 567-577. doi: https://doi.org/10.1016/j.jaccao.2020.09.005
Lam PH, Barac A, Nohria A, Reding KW, Najjar SS, Fonarow GC, Pan K, Sheriff H, Morgan CJ, Chlebowski RT, Klein L, Eaton CB, Howard BV, Ahmed A, Mohammed SF. Temporal Associations and Outcomes of Breast Cancer and Heart Failure in Postmenopausal Women. JACC CardioOncol. 2020 Nov 17;2(4):567-577. doi: 10.1016/j.jaccao.2020.09.005. eCollection 2020 Nov. PMID: 34396268; PMCID: PMC8352239.
Copy Download .nbib Format: NLM
Contextualizing Risk Among Patients With Heart Failure.

JAMA

Greene SJ, Butler J, Fonarow GC.
PMID: 34779819
JAMA. 2021 Dec 14;326(22):2261-2262. doi: 10.1001/jama.2021.20739.

No abstract available.

Cite
Greene SJ, Butler J, Fonarow GC. Contextualizing Risk Among Patients With Heart Failure. JAMA. 2021;326(22):2261-2262doi: 10.1001/jama.2021.20739.
Greene, S. J., Butler, J., & Fonarow, G. C. (2021). Contextualizing Risk Among Patients With Heart Failure. JAMA, 326(22), 2261-2262. https://doi.org/10.1001/jama.2021.20739
Greene, Stephen J, et al. "Contextualizing Risk Among Patients With Heart Failure." JAMA vol. 326,22 (2021): 2261-2262. doi: https://doi.org/10.1001/jama.2021.20739
Greene SJ, Butler J, Fonarow GC. Contextualizing Risk Among Patients With Heart Failure. JAMA. 2021 Dec 14;326(22):2261-2262. doi: 10.1001/jama.2021.20739. PMID: 34779819.
Copy Download .nbib Format: NLM
Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes.

JACC. Heart failure

Khan MS, Solomon N, DeVore AD, Sharma A, Felker GM, Hernandez AF, Heidenreich PA, Matsouaka RA, Green JB, Butler J, Yancy CW, Peterson PN, Fonarow GC, Greene SJ.
PMID: 34895861
JACC Heart Fail. 2021 Nov 30; doi: 10.1016/j.jchf.2021.11.001. Epub 2021 Nov 30.

OBJECTIVES: The authors sought to characterize associations between initiation of metformin and sulfonylurea therapy and clinical outcomes among patients with comorbid heart failure (HF) and diabetes (overall and by ejection fraction [EF] phenotype).BACKGROUND: Metformin and sulfonylureas are frequently prescribed...

Cite
Khan MS, Solomon N, DeVore AD, et al. Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. JACC Heart Fail. 2021;doi: 10.1016/j.jchf.2021.11.001.
Khan, M. S., Solomon, N., DeVore, A. D., Sharma, A., Felker, G. M., Hernandez, A. F., Heidenreich, P. A., Matsouaka, R. A., Green, J. B., Butler, J., Yancy, C. W., Peterson, P. N., Fonarow, G. C., & Greene, S. J. (2021). Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. JACC. Heart failure, . https://doi.org/10.1016/j.jchf.2021.11.001
Khan, Muhammad Shahzeb, et al. "Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes." JACC. Heart failure vol. (2021). doi: https://doi.org/10.1016/j.jchf.2021.11.001
Khan MS, Solomon N, DeVore AD, Sharma A, Felker GM, Hernandez AF, Heidenreich PA, Matsouaka RA, Green JB, Butler J, Yancy CW, Peterson PN, Fonarow GC, Greene SJ. Clinical Outcomes With Metformin and Sulfonylurea Therapies Among Patients With Heart Failure and Diabetes. JACC Heart Fail. 2021 Nov 30; doi: 10.1016/j.jchf.2021.11.001. Epub 2021 Nov 30. PMID: 34895861.
Copy Download .nbib Format: NLM
National Trends in Heart Failure Hospitalization and Readmissions Associated With Policy Changes-Reply.

JAMA cardiology

Agarwal MA, Fonarow GC, Ziaeian B.
PMID: 34730786
JAMA Cardiol. 2022 Jan 01;7(1):115. doi: 10.1001/jamacardio.2021.4419.

No abstract available.

Cite
Agarwal MA, Fonarow GC, Ziaeian B. National Trends in Heart Failure Hospitalization and Readmissions Associated With Policy Changes-Reply. JAMA Cardiol. 2022;7(1):115doi: 10.1001/jamacardio.2021.4419.
Agarwal, M. A., Fonarow, G. C., & Ziaeian, B. (2022). National Trends in Heart Failure Hospitalization and Readmissions Associated With Policy Changes-Reply. JAMA cardiology, 7(1), 115. https://doi.org/10.1001/jamacardio.2021.4419
Agarwal, Manyoo A, et al. "National Trends in Heart Failure Hospitalization and Readmissions Associated With Policy Changes-Reply." JAMA cardiology vol. 7,1 (2022): 115. doi: https://doi.org/10.1001/jamacardio.2021.4419
Agarwal MA, Fonarow GC, Ziaeian B. National Trends in Heart Failure Hospitalization and Readmissions Associated With Policy Changes-Reply. JAMA Cardiol. 2022 Jan 01;7(1):115. doi: 10.1001/jamacardio.2021.4419. PMID: 34730786.
Copy Download .nbib Format: NLM
Beta-Blocker Use and Outcomes in Nursing Home Residents with Heart Failure with Reduced Ejection Fraction.

The American journal of medicine

Bayoumi E, Lam PH, Enders R, Arundel C, Sheriff HM, Brar V, Jurgens CY, Deedwania P, Faselis C, Allman RM, Fonarow GC, Ahmed A.
PMID: 34861195
Am J Med. 2021 Nov 30; doi: 10.1016/j.amjmed.2021.11.004. Epub 2021 Nov 30.

BACKGROUND: Beta-blockers improve clinical outcomes in patients with heart failure with reduced ejection fraction (HFrEF). Less is known about their role in older nursing home residents with HFrEF.METHODS: From the combined OPTIMIZE-HF and Alabama Heart Failure Project data sets,...

Cite
Bayoumi E, Lam PH, Enders R, et al. Beta-Blocker Use and Outcomes in Nursing Home Residents with Heart Failure with Reduced Ejection Fraction. Am J Med. 2021;doi: 10.1016/j.amjmed.2021.11.004.
Bayoumi, E., Lam, P. H., Enders, R., Arundel, C., Sheriff, H. M., Brar, V., Jurgens, C. Y., Deedwania, P., Faselis, C., Allman, R. M., Fonarow, G. C., & Ahmed, A. (2021). Beta-Blocker Use and Outcomes in Nursing Home Residents with Heart Failure with Reduced Ejection Fraction. The American journal of medicine, . https://doi.org/10.1016/j.amjmed.2021.11.004
Bayoumi, Essraa, et al. "Beta-Blocker Use and Outcomes in Nursing Home Residents with Heart Failure with Reduced Ejection Fraction." The American journal of medicine vol. (2021). doi: https://doi.org/10.1016/j.amjmed.2021.11.004
Bayoumi E, Lam PH, Enders R, Arundel C, Sheriff HM, Brar V, Jurgens CY, Deedwania P, Faselis C, Allman RM, Fonarow GC, Ahmed A. Beta-Blocker Use and Outcomes in Nursing Home Residents with Heart Failure with Reduced Ejection Fraction. Am J Med. 2021 Nov 30; doi: 10.1016/j.amjmed.2021.11.004. Epub 2021 Nov 30. PMID: 34861195.
Copy Download .nbib Format: NLM
Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction.

European journal of heart failure

Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M.
PMID: 34894038
Eur J Heart Fail. 2021 Dec 10; doi: 10.1002/ejhf.2397. Epub 2021 Dec 10.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors have recently been recommended as a foundational therapy for patients with heart failure (HF) and reduced ejection fraction (HFrEF) because of their favourable effects on mortality, clinical events and quality of life. While clinical...

Cite
Tomasoni D, Fonarow GC, Adamo M, et al. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2021;doi: 10.1002/ejhf.2397.
Tomasoni, D., Fonarow, G. C., Adamo, M., Anker, S. D., Butler, J., Coats, A. J. S., Filippatos, G., Greene, S. J., McDonagh, T. A., Ponikowski, P., Rosano, G., Seferovic, P., Vaduganathan, M., Voors, A. A., & Metra, M. (2021). Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. European journal of heart failure, . https://doi.org/10.1002/ejhf.2397
Tomasoni, Daniela, et al. "Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction." European journal of heart failure vol. (2021). doi: https://doi.org/10.1002/ejhf.2397
Tomasoni D, Fonarow GC, Adamo M, Anker SD, Butler J, Coats AJS, Filippatos G, Greene SJ, McDonagh TA, Ponikowski P, Rosano G, Seferovic P, Vaduganathan M, Voors AA, Metra M. Sodium-glucose co-transporter 2 inhibitors as an early, first-line therapy in patients with heart failure and reduced ejection fraction. Eur J Heart Fail. 2021 Dec 10; doi: 10.1002/ejhf.2397. Epub 2021 Dec 10. PMID: 34894038.
Copy Download .nbib Format: NLM
Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) registry.

American heart journal

Ullal AJ, Holmes DN, Lytle BL, Matsouaka RA, Sheng S, Desai NR, Curtis AB, Fang MC, McCabe PJ, Fonarow GC, Russo AM, Lewis WR, Heidenreich PA, Piccini JP, Turakhia MP, Perino AC.
PMID: 34932998
Am Heart J. 2021 Dec 18;245:90-99. doi: 10.1016/j.ahj.2021.12.002. Epub 2021 Dec 18.

BACKGROUND: The Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) Registry uses achievement and quality measures to improve the care of patients with atrial fibrillation (AF). We sought to evaluate overall and site-level variation in attainment of these measures...

Cite
Ullal AJ, Holmes DN, Lytle BL, et al. Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) registry. Am Heart J. 2021;245:90-99doi: 10.1016/j.ahj.2021.12.002.
Ullal, A. J., Holmes, D. N., Lytle, B. L., Matsouaka, R. A., Sheng, S., Desai, N. R., Curtis, A. B., Fang, M. C., McCabe, P. J., Fonarow, G. C., Russo, A. M., Lewis, W. R., Heidenreich, P. A., Piccini, J. P., Turakhia, M. P., & Perino, A. C. (2021). Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) registry. American heart journal, 24590-99. https://doi.org/10.1016/j.ahj.2021.12.002
Ullal, Aditya J, et al. "Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) registry." American heart journal vol. 245 (2021): 90-99. doi: https://doi.org/10.1016/j.ahj.2021.12.002
Ullal AJ, Holmes DN, Lytle BL, Matsouaka RA, Sheng S, Desai NR, Curtis AB, Fang MC, McCabe PJ, Fonarow GC, Russo AM, Lewis WR, Heidenreich PA, Piccini JP, Turakhia MP, Perino AC. Achievement and quality measure attainment in patients hospitalized with atrial fibrillation: Results from The Get With The Guidelines - Atrial Fibrillation (GWTG-AFIB) registry. Am Heart J. 2021 Dec 18;245:90-99. doi: 10.1016/j.ahj.2021.12.002. Epub 2021 Dec 18. PMID: 34932998.
Copy Download .nbib Format: NLM
Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model.

ESC heart failure

DeVore AD, Hill CL, Thomas LE, Albert NM, Butler J, Patterson JH, Hernandez AF, Williams FB, Shen X, Spertus JA, Fonarow GC.
PMID: 34791838
ESC Heart Fail. 2021 Nov 17; doi: 10.1002/ehf2.13709. Epub 2021 Nov 17.

AIMS: We aimed to develop a risk prediction tool that incorporated both clinical events and worsening health status for patients with heart failure (HF) with reduced ejection fraction (HFrEF). Identifying patients with HFrEF at increased risk of a poor...

Cite
DeVore AD, Hill CL, Thomas LE, et al. Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. ESC Heart Fail. 2021;doi: 10.1002/ehf2.13709.
DeVore, A. D., Hill, C. L., Thomas, L. E., Albert, N. M., Butler, J., Patterson, J. H., Hernandez, A. F., Williams, F. B., Shen, X., Spertus, J. A., & Fonarow, G. C. (2021). Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. ESC heart failure, . https://doi.org/10.1002/ehf2.13709
DeVore, Adam D, et al. "Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model." ESC heart failure vol. (2021). doi: https://doi.org/10.1002/ehf2.13709
DeVore AD, Hill CL, Thomas LE, Albert NM, Butler J, Patterson JH, Hernandez AF, Williams FB, Shen X, Spertus JA, Fonarow GC. Identifying patients at increased risk for poor outcomes from heart failure with reduced ejection fraction: the PROMPT-HF risk model. ESC Heart Fail. 2021 Nov 17; doi: 10.1002/ehf2.13709. Epub 2021 Nov 17. PMID: 34791838.
Copy Download .nbib Format: NLM
Identifying Treatments for Stage C2 Heart Failure.

JAMA cardiology

Yancy CW, Hernandez AF, Fonarow GC.
PMID: 34643645
JAMA Cardiol. 2021 Oct 13; doi: 10.1001/jamacardio.2021.4024. Epub 2021 Oct 13.

No abstract available.

Cite
Yancy CW, Hernandez AF, Fonarow GC. Identifying Treatments for Stage C2 Heart Failure. JAMA Cardiol. 2021;doi: 10.1001/jamacardio.2021.4024.
Yancy, C. W., Hernandez, A. F., & Fonarow, G. C. (2021). Identifying Treatments for Stage C2 Heart Failure. JAMA cardiology, . https://doi.org/10.1001/jamacardio.2021.4024
Yancy, Clyde W, et al. "Identifying Treatments for Stage C2 Heart Failure." JAMA cardiology vol. (2021). doi: https://doi.org/10.1001/jamacardio.2021.4024
Yancy CW, Hernandez AF, Fonarow GC. Identifying Treatments for Stage C2 Heart Failure. JAMA Cardiol. 2021 Oct 13; doi: 10.1001/jamacardio.2021.4024. Epub 2021 Oct 13. PMID: 34643645.
Copy Download .nbib Format: NLM
Community-level Economic Distress, Race, and Risk of Adverse Outcomes Following Heart Failure Hospitalization among Medicare Beneficiaries.

Circulation

Mentias A, Desai MY, Vaughan-Sarrazin MS, Rao S, Morris AA, Hall JL, Menon V, Hockenberry J, Sims M, Fonarow GC, Girotra S, Pandey A.
PMID: 34743555
Circulation. 2021 Nov 08; doi: 10.1161/CIRCULATIONAHA.121.057756. Epub 2021 Nov 08.

No abstract available.

Cite
Mentias A, Desai MY, Vaughan-Sarrazin MS, et al. Community-level Economic Distress, Race, and Risk of Adverse Outcomes Following Heart Failure Hospitalization among Medicare Beneficiaries. Circulation. 2021;doi: 10.1161/CIRCULATIONAHA.121.057756.
Mentias, A., Desai, M. Y., Vaughan-Sarrazin, M. S., Rao, S., Morris, A. A., Hall, J. L., Menon, V., Hockenberry, J., Sims, M., Fonarow, G. C., Girotra, S., & Pandey, A. (2021). Community-level Economic Distress, Race, and Risk of Adverse Outcomes Following Heart Failure Hospitalization among Medicare Beneficiaries. Circulation, . https://doi.org/10.1161/CIRCULATIONAHA.121.057756
Mentias, Amgad, et al. "Community-level Economic Distress, Race, and Risk of Adverse Outcomes Following Heart Failure Hospitalization among Medicare Beneficiaries." Circulation vol. (2021). doi: https://doi.org/10.1161/CIRCULATIONAHA.121.057756
Mentias A, Desai MY, Vaughan-Sarrazin MS, Rao S, Morris AA, Hall JL, Menon V, Hockenberry J, Sims M, Fonarow GC, Girotra S, Pandey A. Community-level Economic Distress, Race, and Risk of Adverse Outcomes Following Heart Failure Hospitalization among Medicare Beneficiaries. Circulation. 2021 Nov 08; doi: 10.1161/CIRCULATIONAHA.121.057756. Epub 2021 Nov 08. PMID: 34743555.
Copy Download .nbib Format: NLM
Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study.

JAMA neurology

Xian Y, Xu H, O'Brien EC, Shah S, Thomas L, Pencina MJ, Fonarow GC, Olson DM, Schwamm LH, Bhatt DL, Smith EE, Hannah D, Maisch L, Lytle BL, Peterson ED, Hernandez AF.
PMID: 31329212
JAMA Neurol. 2019 Oct 01;76(10):1192-1202. doi: 10.1001/jamaneurol.2019.2099.

IMPORTANCE: Current guidelines recommend direct oral anticoagulants (DOACs) over warfarin for stroke prevention in patients with atrial fibrillation (AF) who are at high risk. Despite demonstrated efficacy in clinical trials, real-world data of DOACs vs warfarin for secondary prevention...

Cite
Xian Y, Xu H, O'Brien EC, et al. Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. JAMA Neurol. 2019;76(10):1192-1202doi: 10.1001/jamaneurol.2019.2099.
Xian, Y., Xu, H., O'Brien, E. C., Shah, S., Thomas, L., Pencina, M. J., Fonarow, G. C., Olson, D. M., Schwamm, L. H., Bhatt, D. L., Smith, E. E., Hannah, D., Maisch, L., Lytle, B. L., Peterson, E. D., & Hernandez, A. F. (2019). Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. JAMA neurology, 76(10), 1192-1202. https://doi.org/10.1001/jamaneurol.2019.2099
Xian, Ying, et al. "Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study." JAMA neurology vol. 76,10 (2019): 1192-1202. doi: https://doi.org/10.1001/jamaneurol.2019.2099
Xian Y, Xu H, O'Brien EC, Shah S, Thomas L, Pencina MJ, Fonarow GC, Olson DM, Schwamm LH, Bhatt DL, Smith EE, Hannah D, Maisch L, Lytle BL, Peterson ED, Hernandez AF. Clinical Effectiveness of Direct Oral Anticoagulants vs Warfarin in Older Patients With Atrial Fibrillation and Ischemic Stroke: Findings From the Patient-Centered Research Into Outcomes Stroke Patients Prefer and Effectiveness Research (PROSPER) Study. JAMA Neurol. 2019 Oct 01;76(10):1192-1202. doi: 10.1001/jamaneurol.2019.2099. PMID: 31329212; PMCID: PMC6647003.
Copy Download .nbib Format: NLM
Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure.

Journal of cardiac failure

Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Felker GM, Filippatos G, Fonarow GC, Fiuzat M, Gomez-Mesa JE, Heidenreich P, Imamura T, Januzzi J, Jankowska EA, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, SeferoviĆ P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S.
PMID: 33663906
J Card Fail. 2021 Mar 01; doi: 10.1016/j.cardfail.2021.01.022. Epub 2021 Mar 01.

In this document, we propose a universal definition of heart failure (HF) as the following: HF is a clinical syndrome with symptoms and or signs caused by a structural and/or functional cardiac abnormality and corroborated by elevated natriuretic peptide...

Cite
Bozkurt B, Coats AJ, Tsutsui H, et al. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021;doi: 10.1016/j.cardfail.2021.01.022.
Bozkurt, B., Coats, A. J., Tsutsui, H., Abdelhamid, M., Adamopoulos, S., Albert, N., Anker, S. D., Atherton, J., Böhm, M., Butler, J., Drazner, M. H., Felker, G. M., Filippatos, G., Fonarow, G. C., Fiuzat, M., Gomez-Mesa, J. E., Heidenreich, P., Imamura, T., Januzzi, J., Jankowska, E. A., Khazanie, P., Kinugawa, K., Lam, C. S. P., Matsue, Y., Metra, M., Ohtani, T., Francesco Piepoli, M., Ponikowski, P., Rosano, G. M. C., Sakata, Y., SeferoviĆ, P., Starling, R. C., Teerlink, J. R., Vardeny, O., Yamamoto, K., Yancy, C., Zhang, J., & Zieroth, S. (2021). Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. Journal of cardiac failure, . https://doi.org/10.1016/j.cardfail.2021.01.022
Bozkurt, Biykem, et al. "Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure." Journal of cardiac failure vol. (2021). doi: https://doi.org/10.1016/j.cardfail.2021.01.022
Bozkurt B, Coats AJ, Tsutsui H, Abdelhamid M, Adamopoulos S, Albert N, Anker SD, Atherton J, Böhm M, Butler J, Drazner MH, Felker GM, Filippatos G, Fonarow GC, Fiuzat M, Gomez-Mesa JE, Heidenreich P, Imamura T, Januzzi J, Jankowska EA, Khazanie P, Kinugawa K, Lam CSP, Matsue Y, Metra M, Ohtani T, Francesco Piepoli M, Ponikowski P, Rosano GMC, Sakata Y, SeferoviĆ P, Starling RC, Teerlink JR, Vardeny O, Yamamoto K, Yancy C, Zhang J, Zieroth S. Universal Definition and Classification of Heart Failure: A Report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure. J Card Fail. 2021 Mar 01; doi: 10.1016/j.cardfail.2021.01.022. Epub 2021 Mar 01. PMID: 33663906.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 191 entries